⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
URGN News
UroGen Pharma Ltd. Ordinary Shares
UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103
globenewswire.com
URGN
UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer
globenewswire.com
URGN
Form 8-K
sec.gov
URGN
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
URGN
Form 8-K
sec.gov
URGN
UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution
globenewswire.com
URGN
UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
globenewswire.com
URGN
UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC
globenewswire.com
URGN
ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial
globenewswire.com
URGN
UroGen Pharma to Present at Upcoming Investor Conferences
globenewswire.com
URGN